Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
$135.23
+0.9%
$167.08
$123.00
▼
$260.19
$7.11B0.86791,455 shs392 shs
Innoviva, Inc. stock logo
INVA
Innoviva
$18.29
-0.6%
$20.53
$18.23
▼
$25.15
$1.30B0.38788,861 shs987 shs
7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
-1.43%-10.21%-14.00%-35.59%-9.14%
Innoviva, Inc. stock logo
INVA
Innoviva
+0.55%-2.44%-12.71%-12.38%-15.87%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
$135.23
+0.9%
$167.08
$123.00
▼
$260.19
$7.11B0.86791,455 shs392 shs
Innoviva, Inc. stock logo
INVA
Innoviva
$18.29
-0.6%
$20.53
$18.23
▼
$25.15
$1.30B0.38788,861 shs987 shs
7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
-1.43%-10.21%-14.00%-35.59%-9.14%
Innoviva, Inc. stock logo
INVA
Innoviva
+0.55%-2.44%-12.71%-12.38%-15.87%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
2.86
Moderate Buy$266.2196.86% Upside
Innoviva, Inc. stock logo
INVA
Innoviva
2.86
Moderate Buy$37.00102.35% Upside

Current Analyst Ratings Breakdown

Latest AXSM and INVA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/18/2026
Innoviva, Inc. stock logo
INVA
Innoviva
Initiated CoverageOverweight$29.00
11/13/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Lower Price TargetEqual Weight$249.00 ➝ $223.00
11/9/2026
Innoviva, Inc. stock logo
INVA
Innoviva
UpgradeHold (C+) ➝ Buy (B)
11/5/2026
Innoviva, Inc. stock logo
INVA
Innoviva
Lower Price TargetOutperform$35.00 ➝ $34.00
11/4/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Lower Price TargetOutperform$284.00 ➝ $272.00
11/3/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Reiterated RatingOutperform
11/3/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Lower Price TargetBuy$256.00 ➝ $239.00
11/3/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Boost Price TargetEqual Weight$247.00 ➝ $249.00
11/3/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Lower Price TargetOutperform$295.00 ➝ $273.00
11/3/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Lower Price TargetBuy$275.00 ➝ $250.00
11/3/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Lower Price TargetOutperform$246.00 ➝ $220.00
(Data available from 11/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
$638.50M11.14N/AN/A$2.00 per share67.62
Innoviva, Inc. stock logo
INVA
Innoviva
$438.32M2.97$5.02 per share3.64$16.00 per share1.14
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
-$183.17M-$3.06N/A36.95N/A-18.18%-198.73%-22.03%N/A
Innoviva, Inc. stock logo
INVA
Innoviva
$271.17M$1.999.198.792.6244.13%22.91%16.67%N/A

Latest AXSM and INVA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/4/2026Q3 2026
Innoviva, Inc. stock logo
INVA
Innoviva
$0.5150-$1.03-$1.5450-$1.03$115.31 million$106.12 million
11/2/2026Q3 2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
-$0.6343-$0.25+$0.3843-$0.25$249.19 million$259.69 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
N/AN/AN/AN/AN/A
Innoviva, Inc. stock logo
INVA
Innoviva
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
1.21
1.42
1.34
Innoviva, Inc. stock logo
INVA
Innoviva
0.23
15.44
14.58

Institutional Ownership

CompanyInstitutional Ownership
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
81.49%
Innoviva, Inc. stock logo
INVA
Innoviva
99.12%

Insider Ownership

CompanyInsider Ownership
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
20.60%
Innoviva, Inc. stock logo
INVA
Innoviva
2.01%
CompanyEmployeesShares OutstandingFree FloatOptionable
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
92552.60 million41.76 millionOptionable
Innoviva, Inc. stock logo
INVA
Innoviva
15971.08 million69.65 millionOptionable

Recent News About These Companies

HC Wainwright Issues Positive Forecast for Innoviva Earnings
Innoviva FY2026 Earnings Forecast Boosted by HC Wainwright
Innoviva (NASDAQ:INVA) Reaches New 12-Month Low - Here's Why
HC Wainwright Issues Negative Forecast for Innoviva Earnings
HC Wainwright Analysts Lower Earnings Estimates for Innoviva
Is Innoviva (INVA) Stock Undervalued Right Now?
Innoviva (INVA) Tops Q3 Earnings Estimates

New MarketBeat Followers Over Time

Media Sentiment Over Time

Axsome Therapeutics stock logo

Axsome Therapeutics NASDAQ:AXSM

$135.23 +1.23 (+0.92%)
As of 09:41 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Innoviva stock logo

Innoviva NASDAQ:INVA

$18.28 -0.12 (-0.63%)
As of 09:41 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.